Aethlon Medical(AEMD)
icon
搜索文档
Innovative Medical Technology Advances with First Patient Enrollments
Newsfile· 2024-11-12 21:00
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - November 12, 2024) - Investorideas.com, a go-to investing platform, releases an industry snapshot looking at the future of medical technology as first patients are enrolled in potential breakthrough trials, featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases. Read the full article on Investorideas.com https://www.investorideas.co ...
Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 13, 2024
Prnewswire· 2024-11-06 21:01
SAN DIEGO, Nov. 6, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal second quarter ended September 30, 2024, at 4:15 p.m. ET on Wednesday, November 13, 2024.Management will host a conference call on Wednesday, November 13, 2024, at 4:30 p.m. ET to review financial results and recent corporate developments. Followi ...
Aethlon Medical to Participate in the 2024 Maxim Healthcare Virtual Summit
Prnewswire· 2024-10-08 20:01
文章核心观点 - 公司专注于开发用于治疗癌症和危及生命的传染病的医疗治疗产品 [1] - 公司的主要产品是Hemopurifier,这是一种临床阶段的免疫治疗设备,旨在治疗癌症和危及生命的病毒感染,以及用于器官移植 [2] - Hemopurifier已在人体研究中证明可去除危及生命的病毒,并在前期研究中证明可从生物液体中去除有害的外泌体,这在癌症和危及生命的传染病中有潜在应用 [2] - Hemopurifier已获得FDA的突破性设备指定,用于治疗对标准护理无反应或无法耐受的晚期或转移性癌症患者,以及治疗未获批准治疗方法的危及生命的病毒感染 [2] 公司概况 - 公司名称为Aethlon Medical,Inc.,是一家专注于开发医疗治疗产品的公司 [1][2] - 公司主要产品是Hemopurifier,这是一种免疫治疗设备,可用于治疗癌症和危及生命的病毒感染,以及器官移植 [2] - Hemopurifier已获得FDA的突破性设备指定,用于治疗晚期或转移性癌症和危及生命的病毒感染 [2] 投资者信息 - 公司CEO兼CFO是James Frakes [1] - 公司将于2024年10月15日在2024年Maxim Healthcare虚拟峰会上进行路演 [1] - 投资者联系人是Susan Noonan [3]
Immunotherapy Clinical Trials - A New Approach to Treating Cancer
Newsfile· 2024-09-19 22:00
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - September 19, 2024) - Investorideas.com, a go-to investing platform, releases the second of a two-part series looking at news and developments for the treatment of cancer and solid tumors focusing on immunotherapy, featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening viral infections. Aethlon's Hemopurifier® is a clinical stage immunotherapeutic dev ...
Aethlon Receives Ethics Committee Approval for Hemopurifier® Cancer Trial in India
Prnewswire· 2024-09-19 20:01
Aethlon Medical Granted Full Ethics Approval from the Medanta Institutional Ethics Committee for a Safety, Feasibility, and Dose Finding Study of its Hemopurifier® in Cancer Patients with Solid Tumors Not Responding to Anti-PD-1 AntibodiesSAN DIEGO, Sept. 19, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that, on September 9, 2024, the Medanta Institutional Ethi ...
Aethlon Medical to Present at Virtual Investor Conferences in September
Prnewswire· 2024-09-17 20:01
SAN DIEGO, Sept. 17, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that management will present at the following virtual investor conferences in September:September 19-20: Life Sciences Investor Forum: James Frakes, Interim Chief Executive Officer and Chief Financial Officer and Steven LaRosa, MD, Chief Medical Officer, will present a company overview at this co ...
Innovation Driving Cancer's Solid Tumors Market
Newsfile· 2024-09-17 19:30
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - September 17, 2024) - Investorideas.com, a go-to investing platform, releases the first of a two-part series looking at news and developments for the treatment of cancer and solid tumors featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening viral infections.Read the full article at Investorideas.comhttps://www.investorideas.com/News/2024/biotech/0917 ...
Aethlon Medical Announces Activation of Royal Adelaide Hospital to Begin Patient Screening and Enrollment in Hemopurifier® Cancer Trial
Prnewswire· 2024-09-16 20:01
Aethlon's Trial is a Safety, Feasibility, and Dose Finding Study of the Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 AntibodiesSAN DIEGO, Sept. 16, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that the Cancer Clinical Trial Unit at Royal Adelaide Hospital was activated on September 10, 2024 to begin screening and enrolling patients in ...
Aethlon Medical to Present at the Life Sciences Investor Forum September 19th
GlobeNewswire News Room· 2024-09-13 20:35
SAN DIEGO, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, is pleased to announce that Jim Frakes, interim CEO and CFO and Steve LaRosa, Chief Medical Officer, will present live at the Life Sciences Investor Forum, hosted by VirtualInvestorConferences.com, on September 19th 2024. DATE: September 19th TIME: 1:30 PM ETLINK: https://bit.ly/3XjDJkLAvailable for 1x1 meet ...
Aethlon Medical(AEMD) - 2025 Q1 - Earnings Call Transcript
2024-08-15 06:45
财务数据和关键指标变化 - 截至2024年6月30日,公司现金余额约为9.1百万美元 [22] - 2024年6月30日季度的合并经营费用约为2.6百万美元,较2023年6月季度的3.4百万美元下降约24% [23] - 费用下降主要由于一般管理费用减少约600,000美元,专业费用减少约300,000美元,部分被薪酬及相关费用增加约100,000美元所抵消 [23][24][25][26] - 剔除员工离职相关300,000美元费用后,公司经营费用实际下降超过100万美元 [28] - 由于上述因素,公司2024年6月季度净亏损约为2.6百万美元,较2023年6月季度的3.3百万美元减少约700,000美元 [27] 各条业务线数据和关键指标变化 - 公司正在继续研究和临床开发其Hemopurifier治疗性血液过滤系统,该系统旨在捕获和去除有害的外泌体和致命性病毒 [11] - Hemopurifier在肿瘤学、传染病和器官移植等领域有潜在应用 [11] 各个市场数据和关键指标变化 - 公司在澳大利亚获得两家医院的伦理委员会批准,开展Hemopurifier在固体瘤患者中的安全性、可行性和剂量探索性临床试验 [13][14] - 预计2024年9月中旬至下旬开始患者入组 [15] - 公司还在评估在印度开展COVID-19临床试验的可能性 [21] 公司战略和发展方向及行业竞争 - 公司正在推进肿瘤适应症的临床开发,这是公司的两大目标之一 [12] - Hemopurifier有望提高抗PD-1疗法的治疗反应率,因为肿瘤产生的外泌体被认为导致了对这些疗法的耐药性 [19] - 公司还有望应对致命性包膜病毒引发的疫情和大流行,因为Hemopurifier已显示可捕获多种感兴趣的包膜病毒 [20] 管理层对经营环境和未来前景的评论 - 公司正在取得进展,实现了Frakes先生上任时提出的两大目标:推进肿瘤适应症和降低费用 [12] - 费用下降趋势应该会持续,但随着临床试验活动的增加,费用也可能会有所上升,两者可能会相互抵消 [32] 其他重要信息 - 公司已完成临床试验所需的各项准备工作,正在等待医院的研究管理办公室批准 [15][37] - 公司还计划在澳大利亚增加第三个试验点,并正在评估在印度开展COVID-19临床试验 [16][21] 问答环节重要的提问和回答 问题1 **Marla Marin 提问** 如果剔除员工离职相关费用,公司的经营费用水平是否可以作为未来的一个较好的参考基准,考虑到随着临床开发力度的增加,研发费用可能会有所上升 [31] **James Frakes 回答** 费用方面存在不同的变动趋势:一方面,公司更换了律师和会计事务所,预计未来专业费用会进一步下降;另一方面,随着9月份澳大利亚临床试验的启动,相关费用可能会有所上升,两者可能会相互抵消,难以准确预测 [32] 问题2 **Marla Marin 提问** 关于在澳大利亚的临床试验,公司是否需要提供培训,培训过程是否会比较短暂,在公司人员离开后如何提供持续支持 [33] **Steven LaRosa 回答** 公司将在9月份进行为期2-3天的现场启动培训,之后还会在10月份组织一次调研者会议,届时公司人员会亲自前往。同时公司还计划聘请一名技术人员常驻当地,随时为试验点提供支持 [34][35] 问题3 **Marla Marin 提问** 公司在准备临床试验所需的各项文件方面是否已全部完成 [36] **Steven LaRosa 回答** 是的,公司已完成所有需要提交的文件和响应,现在正在等待医院研究管理办公室的批准 [37]